(The FASEB Journal. 2001;15:618-626.)
© 2001 FASEB
Endothelin-1 protects astrocytes from hypoxic/ischemic injury
MAGGIE C. Y. HO*,
AMY C. Y. LO*,
HIROKI KURIHARA
,1,
ALBERT C. H. YU
,
STEPHEN S. M. CHUNG* and
SOOKJA K. CHUNG*2
* Institute of Molecular Biology, The University of Hong Kong, Pokfulam;
Department of Biology, The Hong Kong University of Science and Technology, Clear Water Bays, Hong Kong, China;
Department of Cardiovascular Research, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
2Correspondence: Institute of Molecular Biology, The University of Hong Kong, South Wing, 8/F Kadoorie, Biological Science Bldg., Pokfulam Road, Hong Kong, China. E-mail: skchung{at}hkucc.hku.hk
 |
ABSTRACT
|
|---|
Under pathological conditions such as ischemia (I), subarachnoid
hemorrhage, and Alzheimers disease, astrocytes show a large increase
in endothelin (ET) -like immunoreactivity. However, it is not clear
whether ET is protective or destructive to these cells during brain
injury. Using astrocytes from ET-1-deficient mice, we determined the
effect of ET-1 on these cells under normal, hypoxic (H), and
hypoxic/ischemic (H/I) conditions. Under normal culture conditions,
astrocytes from wild-type and ET-1-deficient mice showed no difference
in their morphology and cell proliferation rates. ET-3 and
ETA receptor mRNAs were up-regulated whereas
ETB receptor mRNA was down-regulated in ET-1-deficient
astrocytes, suggesting that ET-1 and ET-3 may complement each others
functions and that the expressions of these endothelins and their
receptors are regulated by a complex feedback mechanism. Under H and
H/I conditions, ET-1 peptide and mRNA were up-regulated in wild-type
astrocytes, and the astrocytes without ET-1 died faster than the
wild-type astrocytes, as indicated by greater efflux of lactate
dehydrogenase. The present study suggests that astrocytes without ET-1
are more vulnerable to H and H/I injuries and that the up-regulation of
astrocytic ET-1 is essential for the survival of astrocytes.Ho,
M. C. Y., Lo, A. C. Y., Kurihara, H., Yu, A. C. H., Chung, S. S. M., Chung, S. K. Endothelin-1 protects
astrocytes from hypoxic/ischemic injury.
Key Words: Endothelin-3 endothelin receptors cell survival lactate dehydrogenase ET-1-deficient mice
 |
INTRODUCTION
|
|---|
ENDOTHELIN (ET)-1, a 21-amino-acid peptide originally
isolated from porcine aortic endothelial cells, is one of the most
potent vasoconstrictors known (1)
. Three
isopeptidesET-1, ET-2, ET-3have been identified (2)
.
They exert various physiological actions by binding to two specific
G-protein-coupled receptors subtypes, ETA and
ETB receptors in mammalian cells (3
, 4)
.
ETA receptor has greater affinity for ET-1 and
ET-2 whereas ETB receptor binds to ET-1, ET-2,
and ET-3 equally well. Numerous reports on the expression, regulation,
actions and bindings of ETs in various tissues other than endothelial
cells have accumulated since the first isolation of ET-1
(5)
. Apart from being the strong vasoconstrictor (1
, 6
7
8)
, ET-1 is known to be mitogenic (9
10
11
12
13)
and
anti-apoptotic (14
, 15)
in many cell types including
endothelial cells and astrocytes in an autocrine and paracrine manner.
Within the central nervous system (CNS), ET-1 is expressed in many
neuronal groups (16
17
18)
and in glial cells under
pathological conditions (19)
. The distribution of ET-1 and
its receptors, ETA and ETB,
in different sites of the CNS suggests that it may influence a wide
range of CNS controlled functions. Under pathological conditions of CNS
such as stroke, hypoxic/ischemic (H/I) and infarction, subarachnoid
hemorrhage, and Alzheimers disease, ET-like immunoreactivity has been
detected in astrocytes of brain (8
, 20
21
22
23
24)
. Recently, we
have shown that astrocytes in the damaged region of H/I mouse brain
express a high level of ET-1 mRNA (25)
, indicating that
increased endothelin-like immunoreactivity in the astrocytes is due to
increased expression of ET-1 gene rather than increased binding of
ET-1. These observations implicated a role of astrocytic ET-1 in the
pathogenesis during H/I conditions. However, it is not clear whether
ET-1 serves a protective role or hastens the death of the cells under
H/I.
The ET-1-deficient mice have been generated in order to understand the
physiological role of ET-1, but they die within minutes after birth due
to craniofacial and cardiac deformities (26)
. It has been
suggested that ET-1 is a growth promoting factor for neural crest cells
and their derived tissues including branchial arches during early
development, through its action on the ETA
receptor since ET-1 and ETA receptor-deficient mice have
similar defects in branchial arch derived tissues (27)
.
This suggestion has been further supported by in situ
hybridization analysis in which ET-1 mRNA has been shown to be
transiently expressed in the branchial epithelium and mesodermal core
between embryonic day 9.5 (E9.5d) and 10.5 (E10.5d) (28)
,
whereas ETA receptor mRNA was concurrently expressed in the
neighboring mesenchymal cells (27)
.
To understand the significance of astrocytic ET-1 during normal, H, and
H/I conditions, astrocytes were isolated and cultured from the embryos
at embryonic day 17.5 (E17.5d) of wild-type
(ET-1+/+) and ET-1-deficient
(ET-1-/-) mice. Astrocytes deficient in ET-1
were found to be more vulnerable to the H and/or H/I conditions. We
also found that ET-1 deficiency led to up-regulation of ET-3 and
ETA receptor and reduced expression of ETB
receptor mRNA. These observations suggest that ET-1 and ET-3 may
complement each others function and that the expression of these
endothelins and their receptors is coordinately controlled.
 |
MATERIALS AND METHODS
|
|---|
ET-1 knockout mice
ET-1-deficient mice were obtained from Dr. Kurihara
(26)
. To collect E17.5d embryos of three different
genotypeswild-type (ET-1+/+), heterozygous
(ET-1+/-), and homozygous (ET-1-/-)male
and female ET-1+/- mice were mated. The genotypes of ET-1
knockout mice were determined by polymerase chain reaction (PCR) using
genomic DNA isolated from tails. Forward primer (5'-ATC AGC AGC CTC TGT
TCC-3') from the region of the inserted
neor gene and reverse primer (5'-CGT GGC
CAG CCA TTG TAG AC-3') from exon 5 of ET-1 gene were used to screened
for the mutant allele. At the same time, another forward primer (5'-AAG
CGC TGT TCC TGT TCT TCC-3') from the region of exon 2 of ET-1 gene and
the same reverse primer were used to screen for the normal allele. 30
cycles (94°C for 1 min, 59°C for 1 min, and 72°C for 1 min) were
used to amplify for 1 kb product.
Astrocyte cultures
Primary cortical astrocytic cultures were prepared from the
cerebral cortex of E17.5-d mouse embryos as described previously
(29)
. In brief, the cerebral cortex freed of meninges was
cut into small cubes in DMEM/F12. Cells were mechanically dissociated
from the matrix by vortexing for 1 min and 30 s, then sieved
through a 10 µm sterile nylon mesh filter. The cell suspension was
subsequently plated in a T75 culture flask with normal growth medium,
DMEM/F12 supplemented with 10% fetal calf serum (FCS). All cultures
were incubated at 37°C with 95% air/5% CO2.
The cells were used for experiments after 4 wk. For the experiments
that included astrocytes from both wild-type and ET-1 knockout mouse
embryos, astrocytes of the same genotype were trypsinized, pooled, and
seeded onto T75 culture flasks when the cultures reached confluency
after 2 wk. Cells were used for experiments after incubation in the
same conditions for 2 more weeks. The purity of the astrocytes was
determined by immunocytochemistry using a rabbit anti-GFAP polyclonal
antibodies (Dako, Carpinteria, Calif.) as mentioned below.
ET-1 ELISA assay
The astrocyte-conditioned media were collected at the indicated
times. To determine the amounts of ET-1 in the media, the media were
first concentrated by passing through C2 columns
(Amersham, Nutley, N.J.). The amount of ET-1 present in the media were
detected by using an ET-1 ELISA system (Amersham).
Immunocytochemistry
Monolayers of astrocytes grown on glass coverslips in 24-well
plates to
90% confluence were fixed in 4% paraformaldehyde for 15
min at 25°C and postfixed with 95%/5% ethanol/acetic acid for 15
min at -20°C. Cells were then incubated for 24 h at 4°C with
primary antibody, rabbit anti-GFAP polyclonal antibodies (Dako),
diluted 1:200 in phosphate-buffered saline (PBS) with 5% normal goat
serum. After subsequent washing in PBS, cells were reincubated with
TRITC-labeled goat anti-rabbit antibody (Zymed Laboratories, San
Francisco, Calif.), diluted 1:5000 in PBS for 1 h at 25°C.
Control experiments without the primary antibody were done in parallel.
Fluorescent images of the cells were obtained with a confocal
microscope (Carl Zeiss, Thornwood, N.Y.).
Cell proliferation assay
Confluent astrocytes were trypsinized and seeded at a density of
1.7 x 104 cells/well in 96-well plates in
normal growth culture medium. After 24 h, culture medium was
replaced by serum-free medium, and cells were incubated for an
additional 24 h. Astrocytes were then treated with 0.5% FCS or
10% FCS supplemented growth medium for 24 h. The number of viable
cells in each well was estimated by measuring the rate of mitochondrial
metabolism of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium
bromide (MTT) using a cell proliferation assay kit (Boehringer
Mannheim, Indianapolis, Ind.) according to the manufacturers
instructions.
Hypoxia and hypoxia/ischemia
In vitro H and H/I culture conditions were performed
as described previously (30
, 31)
. All experiments were
performed with an assay buffer containing 119 mM NaCl, 4.7 mM KCl, 1.0
mM MgSO4, 2.5 mM CaCl2, 1.2
mM KH2PO4, 25 mM
NaHCO3, 10 mM glucose at pH 7.4 and were filter
sterilized. For all H experiments, the buffer for culturing astrocytes
was first purged with N2 for 30 min to replace
the O2 and then equilibrated with a gas mixture
consisting of 5% CO2/85%
N2/10% H2 for 20 min in
order to adjust the pH of the buffer. Astrocytes were then subjected to
H for various times (4, 6, 8, and 24 h) in an anaerobic chamber (Forma
Scientific, Marietta, Ohio) that preconditioned with 5%
CO2/85% N2/10%
H2. The O2 content in the
chamber was measured by an oxygen electrode (Microelectrodes, Inc.,
Nashua, N.H.), and less than 10 ppm O2 was
detected. In vitro H/I was induced in astrocyte cultures by
subjecting cultures to a combination of H and glucose-free conditions
for various times (4, 6, 8, and 24 h). For some of the experiments, 10
nM ET-1 peptide (Peninsula Laboratories, Belmont, Calif.) was added to
the medium before H/I treatment. The solvent for the peptide (100%
acetonitrile with 0.1% trifluroacetic acid) was added to the medium of
control cells.
Cell viability assay
Total cell viability was determined by the lactate dehydrogenase
(LDH) assay (Boehringer Mannheim). At the indicated times, a small
aliquot of the medium was removed from the culture flask and the amount
of LDH was measured. Total cellular LDH was determined after adding
Triton X-100 to a final concentration of 1% in a T75 tissue culture
flask. LDH released during the experiment was expressed as a percentage
of total cellular LDH.
Reverse transcriptase PCR
Whole-cell RNA was isolated by TRI
REAGENT® (Molecular Research Center, Cleveland,
Ohio) according to the manufacturers protocol. The conditions for
reverse transcriptase (RT)-PCR have been optimized such that the amount
of RNA added for RT reaction, the amount of reverse-transcribed cDNA,
and the amount of primer pairs used for PCR as well as the number of
amplification cycles were chosen within the linear range of the
reaction. Total RNA (1.5 µg) after hybridization to 0.5 µg
Oligo(dT)18 was used to generate cDNA by
SuperscriptTM II RNase H- (Gibco BRL, Gaithersburg, Md.)
with the respective synthesis buffer, 10 mM DTT, and 1 mM dNTP for
1 h at 42°C. The cDNA was then amplified by PCR using
Taq polymerase in a reaction volume of 50 µl. Specific
primer pairs were constructed based on the reported mouse sequences for
ET-1 (CTT CCC AAT AAG GCC ACA GAC CAG/AGC CAC ACA GAT GGT CTT GCT AAG;
expected PCR product: 426 bp), for ET-3 (GAT CAG AGA GGG GCT GTG AAG
AG/AAG TAC AAC GCA AGC GTG TCC ACG; expected PCR product: 360 bp), for
ETA ET receptor (ACC GCC ATT GAA ATC GTC TCC
ATC/TTA GCA GCA AGA AGC TGA GCA GTT C; expected PCR product: 445 bp),
and for ETB ET receptor (TGA CGC CAC CCA CTA AGA CCT CC/GCC
TTC TGT ATG AAG GGC ACC AG; expected PCR product: 409 bp). For
semi-quantitative analysis of the ET system gene expression, mouse
GAPDH gene was coamplified in the same PCR reaction and used as the
internal control to calculate the densitometric results. The primers
used for amplifying GAPDH gene were TGA TGA CAT CAA GAA GGT GGT GAA
G/TCC TTG GAG GCC ATG TAG GCC AT; expected PCR product, 239 bp. Both
primer pairs were added simultaneously to the PCR reaction vials. After
4 min at 94°C, 29 to 30 cycles were performed at 94°C, 30 s;
61°C, 30 s; 72°C, 30 s. PCR products were examined on
1.75% agarose gel with ethidium bromide staining. Gel images were
captured with the Eagle Sight system (Stratagene, San Diego, Calif.).
The ratio of the ET system to GAPDH genes expression was determined by
comparing the densities of bands for the ET system genes and for the
GAPDH gene using PhosphorImager (Molecular Dynamics, Sunnyvale,
Calif.).
Western blot analysis
Protein concentrations were determined by the Bio-Rad protein
assay (Bio-Rad Laboratories, Hercules, Calif.) and volumes of the
sample used were adjusted to give equal loading to each lane. Proteins
were separated by 7.5% polyacrylamide gel and transferred onto a
nitrocellulose filter. Nonspecific sites were blocked by incubating
with 5% nonfat dry milk powder in TBS buffer consisting of 0.05 M
Tris, 0.15 M NaCl, pH 7.4 for 1 h. The nitrocellulose filter was
then incubated at room temperature for 1 h with 1:200 dilution of
mouse anti-GFAP antibody (Sigma, St. Louis, Mo.). Detection was
performed with peroxidase-conjugated goat anti-mouse antibody with 1:
5000 dilution. Peroxidase activity was visualized using the ECL method
(Amersham).
Statistical analysis
For semi-quantitative RT-PCR analysis, statistical significance
was determined by paired t test using Graphpad prism (San
Diego, Calif.). For all other experiments, statistical analysis was
determined by one-way analysis of variance (ANOVA) and then Tukeys
multiple comparison tests using Graphpad prism.
 |
RESULTS
|
|---|
Increased ET-1 expression in wild-type primary cortical astrocytes
under H/I conditions
Results from our previous experiments showed that astrocytes in
the H/I damaged region of the mouse brain have a large increase in the
level of ET-1 mRNA (25)
. To study the significance of
astrocytic ET-1 during H and H/I conditions, we established primary
cultures of astrocytes from wild-type embryos at E17.5d. The purity of
the primary astrocytes was assessed by immunocytochemical staining
using the polyclonal antibody specific for GFAP (see Fig. 2B
). Approximately 95% of the cells were GFAP positive,
suggesting that the normal culture conditions were optimum for
maintaining astrocytes with high purity. As shown in Fig. 1
, under H conditions, the amount of ET-1 secreted by the primary
cortical astrocytes was increased after 24 h. Under H/I
conditions, increased ET-1 secretion was evident as early as 4 h and
with a much higher release at 8 h. Under normal conditions, there
is no observable change in the ET-1 level. ET-1 level was not measured
beyond 8 h of H/I because a significant number of cells were dead
after that time. These results clearly indicated that in
vitro H/I conditions closely resembles in vivo H/I
conditions (25)
and that an increase in ET-1 mRNA leads to
increase of ET-1 peptide.

View larger version (92K):
[in this window]
[in a new window]
|
Figure 2. Micrographs illustrating the morphology (A, C) and GFAP
immunostaining (B, D) of confluent astrocyte cultures
from wild-type (ET-1+/+) and ET-1-deficient
(ET-1-/-) mouse embryos. The morphology and intensity of
glial fibrillary acidic protein (GFAP) staining are indistinguishable
in ET-1+/+and ET-1-/- astrocytes.
|
|

View larger version (12K):
[in this window]
[in a new window]
|
Figure 1. Amount of ET-1 peptide secreted by primary cortical astrocytes during
various time points after normal (N), hypoxia (H), and hypoxia/ischemia
(H/I) conditions.
|
|
Characterization of normal and ET-1-deficient astrocytes in culture
We determined the phenotype of astrocytes from either wild-type or
ET-1-deficient mice cultured under normal conditions. As shown in Fig. 2A
, C
, under normal culture conditions, there was no
significant morphological difference in astrocytes from wild-type and
ET-1-deficient mice. Both cells expressed GFAP, characteristic of
astrocytes, as determined by staining with antibodies against this
protein (Fig. 2B
, D
). The rate of cell proliferation was determined by MTT
assays. As shown in Fig. 3
, the growth rates of wild-type and ET-1-deficient astrocytes in normal
(10% serum) as well as low serum (0.5% serum) media were
indistinguishable.

View larger version (11K):
[in this window]
[in a new window]
|
Figure 3. Histogram showing the rate of cell proliferation (MTT assay) in
ET-1+/+ and ET-1-/- astrocytes. The % of
cell growth for ET-1+/+ and ET-1-/-
astrocytes in either 0.5% FCS or 10% FCS was not significantly
different. Data are expressed as mean ± SE of 6
independent cultures.
|
|
Abnormal expression of ET-3 and ETA and ETB
receptor in ET-1 deficient astrocytes
The expression of ET-1, ET-3 mRNAs as well as the mRNAs of their
receptors in wild-type and ET-1-deficient astrocytes were further
characterized to see whether there is any change in their expression to
compensate for ET-1 deficiency. ET-3 is an ET isoform that is normally
expressed in the brain. It differs from ET-1 by 6 of the 21 amino acids
(2)
. These two endothelins are thought to share a number
of functions (10
, 32)
. Therefore, it is important to
determine whether ET-3 is increased in the ET-1-deficient cells in
order to compensate for the ET-1 deficiency. The levels of ET-3 mRNA in
wild-type and ET-1-deficient astrocytes were compared by RT-PCR. The
results, shown in Fig. 4B-2
indicate that the level of ET-3 mRNA in ET-1-deficient
astrocytes was
2.5-fold higher than that of wild-type astrocytes,
suggesting that ET-3 is overexpressed to compensate for the absence of
ET-1. Levels of ETA and ETB receptor
mRNAs, the two receptors for ET-1 and ET-3, were also examined by
RT-PCR. Whereas ETA receptor mRNA was increased in
ET-1-deficient cells, ETB receptor mRNA was lowered in
these cells (Fig. 4B-3
, -4
).

View larger version (41K):
[in this window]
[in a new window]
|
Figure 4. Semi-quantitative RT-PCR analysis of ET system gene expression in
primary astrocytes of wild-type (ET-1+/+) or ET-1 knockout
(ET-1-/-). A) Ethidium bromide-stained
agarose gels of ET-1, ET-3, ETA, and ETB RT-PCR
products. B) mRNA expressions of 1) ET-1,
2) ET-3, 3) ETA, and
4) ETB receptors under basal conditions were
compared to that of GAPDH. The levels of gene expression were
calculated as the ratios of band intensity of ET-related genes to that
of GAPDH. Data are presented as mean ± SE,
n = 5 to 7. Statistical differences between
ET-1+/+ and ET-1-/- astrocytes
(P<0.001 for ET-3, P<0.01 for
ETA receptor, P<0.05 for ETB
receptor, one-way ANOVA and then Tukeys multiple comparison tests)
are shown on the histogram. M-100 bp DNA ladder.
|
|
ET-1-deficient astrocytes are more sensitive to hypoxic/ischemic
stress
As mentioned above, in vitro H or H/I conditions
clearly simulated brain H/I in vivo in that ET-1 synthesis
was induced. To determine the effects of ET-1 secreted by astrocytes
during H/I conditions, wild-type and ET-1-deficient astrocytes were
cultured under H and H/I conditions. LDH released into the medium was
used as measures of cell death. As shown in Fig. 4
, ET-1-deficient
astrocytes were much more sensitive to H/I stress. As early as 4 h
after H/I,
80% of the LDH activity in ET-1-deficient astrocyte
culture was released into the medium, indicating that the plasma
membranes of
80% of these cells were leaky or that 80% of these
cells were dying. In contrast, only
30% of the LDH activity was
detected in the medium of the wild-type astrocyte culture (Fig. 5
) with induction of ET-1 synthesis (data not
shown). By 8 h, all cellular LDH of ET-1-deficient astrocytes was
released into the medium, whereas only
40% of LDH activity was
found in the medium of the wild-type astrocytes.

View larger version (15K):
[in this window]
[in a new window]
|
Figure 5. The % of lactate dehydrogenase (LDH) released by
ET-1+/+ and ET-1-/- astrocytes during normal
conditions (N), hypoxia (H), and hypoxia/ischemia (H/I). Results are
shown as mean ± SE of five different cultures. The %
of LDH released was significantly different between ET-1+/+
and ET-1-/-astrocytes after 4, 6, 8 h H/I
(*P<0.001, one-way ANOVA and then Tukeys multiple
comparison test) and 24 h H (**P<0.05, one-way
ANOVA and then Tukeys multiple comparison test).
|
|
Regulation of ET-3 and ETA and ETB
receptors during hypoxia and hypoxia/ischemia in normal and ET-1
deficient astrocytes
To further investigate the interacting regulation of
endothelins and their receptors, the levels of ET-3 and ETA
receptors and ETB receptor in wild-type and ET-1-deficient
cells were determined under H and H/I conditions. As shown in
Fig. 6
, in wild-type astrocytes, H and H/I did not change the expression of
ET-3 and ETA receptor significantly (Fig. 6B
, C
). However, in ET-1-deficient cells, both ET-3 and
ETA receptor expression were significantly reduced
under these conditions (Fig. 6B
, C
). There was a significant
reduction of ETB receptor level in wild-type astrocytes
under H and H/I (Fig. 6D
); a smaller reduction of this
endothelin receptor was observed in ET-1-deficient astrocytes under
H/I.

View larger version (33K):
[in this window]
[in a new window]
|
Figure 6. Semi-quantitative RT-PCR analysis of A)
ET-1, B) ET-3, C) ETA, and
D) ETB receptor mRNAs after 6 h hypoxia
(H) and hypoxia/ischemia (H/I). The results, ET system gene
expression/GAPDH ratio, were expressed as the percentage of values over
that of normal. Data are presented as mean ± SE.
n = 3 to 5. Statistical significance between different
treatments to ET-1+/+ or ET-1-/- astrocytes
(P<0.05 or P<0.01, one-way ANOVA and
then Tukeys multiple comparison test) are shown on the histogram.
|
|
Effects of ET-1 treatment on hypoxic/ischemic astrocytes
To confirm that the increased sensitivity of
ET-1-deficient astrocytes to H/I stress is due to the lack of ET-1 and
not to other defects generated during the process of knocking out ET-1
gene, ET-1 was added to the media of astrocytes under H/I to a final
concentration of 1, 10, and 100 nM. As shown in Fig. 7
, addition of 10 nM ET-1 partially normalized the LDH released by the
ET-1-deficient astrocytes under H/I (P<0.001, one-way ANOVA
and then Tukeys multiple comparison tests). However, adding ET-1 at a
higher dose (100 nM) to the culture caused a significant rebound in the
LDH level (P<0.01, one-way ANOVA and then Tukeys multiple
comparison test). The amount of LDH released by the ET-1-deficient
astrocytes cultured with exogenous 10 nM ET-1 was significantly lowered
vs. those cultured with 1 nM also (P<0.01, one-way ANOVA
and then Tukeys multiple comparison test).

View larger version (14K):
[in this window]
[in a new window]
|
Figure 7. The % of LDH released into the medium by ET-1-/-
astrocytes culturing in normal condition (N) and hypoxia/ischemia (H/I)
for 6 h with ET-1 treatment. Data were expressed as mean ±
SE of four to seven independent cultures. Note that there
is a significant drop in the LDH release after addition of 10 nM ET-1
to the ET-1-/- astrocytes (P<0.001,
one-way AVONA and then Tukeys multiple comparison test).
|
|
Hypoxic/Ischemic induction of GFAP in normal and ET-1 deficient
astrocytes
GFAP is the specific marker for astrocytes. The expression of this
gene is induced upon H/I or other injuries. We therefore wanted to see
whether ET-1 affects the expression of this gene in astrocytes under
H/I. As shown in Fig. 8
, the GFAP content was increased when wild-type astrocytes were cultured
in H/I conditions. There was no increase in GFAP content in
ET-1-deficient cells under H/I. However, the level of GFAP was induced
only when exogenous ET-1 was added to the ET-1-deficient astrocytes
under H/I conditions.

View larger version (41K):
[in this window]
[in a new window]
|
Figure 8. Western blotting of GFAP expression in ET-1+/+ and
ET-1-/-astrocytes culturing in normal (N) and
hypoxia/ischemia (H/I) conditions for 6 h, with or without the
addition of 10 nM ET-1. Note that the GFAP expression in
ET-1-/- astrocytes was induced by the addition of 10 nM
ET-1.
|
|
 |
DISCUSSION
|
|---|
Astrocytes have many important functions in the brain because they
are responsible for the maintenance of the neuronal cells nearby. They
are involved in the glutamate uptake and therefore they may be
responsible for preventing excitotoxic neuronal injury (33
, 34)
. They regulate the levels of critical extracellular ions
such as K+ and H+
(35)
and are also responsible for the antioxidant defense
in the brain (36
37
38)
. Under certain pathological
conditions such as H/I and infarction, subarachnoid hemorrhage, and
Alzheimers disease, the astrocytes at the sites of degenerating
neurons experiencing these stresses express ET-like immunoreactivity
(8
, 20
21
22
23
24)
. By in situ hybridization, we
showed that H/I injury causes a dramatic increase in ET-1 mRNA
(25)
, indicating that increased ET immunoreactivity in the
astrocytes of H/I brain is due primarily to increased synthesis of
ET-1. All these observation suggest that the ETs may have an important
function to response to these stresses. However, it is unclear whether
ET-1 has a beneficial or a destructive function under these
pathological conditions.
Although the ET-1-deficient mice are not viable (26)
, they
provide a source of ET-1-deficient astrocytes for the analysis of ET-1
functions. We showed that under normal culture conditions, the
ET-1-deficient astrocytes were almost indistinguishable from wild-type
astrocytes in terms of morphology and growth rate. We do not know
whether this is because ET-1 has no function in astrocytes under normal
conditions or whether its functions under these conditions are taken
over by ET-3, which is overexpressed in ET-1-deficient cells.
In the ET-1-deficient astrocytes, ET-3 and ETA receptor
mRNAs are increased whereas ETB receptor mRNA is reduced.
ET-3 is thought to have functions similar to ET-1. Its up-regulation in
ET-1-deficient cells suggests that the expression of this gene may be
mediated by feedback mechanism, possibly through their common receptors
ETA and ETB. The increase
in ETA and a decrease in
ETB in the absence of ET-1 also suggest that the
expression of these two genes may be regulated by some feedback
mechanisms involving ET-1 under normal conditions. This feedback
regulation of ETs and their receptors is also evident during H/I
stress, as ET-3 and ETA and ETB receptor
mRNAs are down-regulated in ET-1-deficient cells.
We cultured the astrocytes in the absence of oxygen and oxygen/glucose
to simulate, respectively, H and H/I in vivo. We found that
the in vitro H/I conditions elicited the induction of ET-1
synthesis in the astrocytes similar to in vivo H/I
(25)
. Recently, hypoxia-inducible factor 1 binding site
has been identified near the transcription start site of the ET-1 gene
(39)
. Our present model may help to pave the way to
increase our understanding of the mechanism of regulation of ET-1
synthesis by H/I conditions.
The specific induction of ET-1 during H/I suggests that ET-1 may have
an important function to counteract this stress. We showed that
ET-1-deficient astrocytes were much more sensitive to H/I than normal
astrocytes, indicating that ET-1 has an important function of
protecting the astrocytes against H/I stress. ET-1 and ET-3 are thought
to exert similar effects on astrocytes with regard to binding to
ETB receptor, inositol phospholipid turnover,
regulation of intracellular calcium, and mitogenesis (10
, 32)
, suggesting that ET-1 and ET-3 can compensate for each
others function including protection from cell death. However, even the
increased level of ET-3 in the ET-1 deficient cells does not confer
protection against H and H/I stress. This indicates that some functions
of ET-1 cannot be replaced by ET-3 although both bind
ETB receptor.
Despite the possible protective effect of ET-1 on astrocytes during H
and H/I, the ETB receptor mRNA was found to be
down-regulated by
3040% under these conditions. This is most
likely in response to the large increase in ET-1 during H and H/I. As
discussed later, too much ET-1 is toxic to the cells. Reducing
ETB receptor may reduce this toxicity. Also, the
protective effect of ET-1 in the wild-type astrocytes may act through
the ETA receptor as the mRNA level of this
receptor was not altered by H or H/I. It is possible that the
ETA receptor may partly take over
ETBs role when the ETB
receptor is down-regulated. As in astrocytes prepared from the
ETB receptor-deficient rat, the
ETA receptor becomes coupled to the
Gi/o protein, which was originally found to be
involved in the ETB receptor mediated protein
kinase activation for mitogenic action of ET-1 and DNA synthesis in
astrocytes (40)
.
Addition of ET-1 to ET-1-deficient astrocytes provided partial
protection for these cells, supporting our notion that a lack of ET-1
made the cells more sensitive to H/I. The partial protection provided
by exogenously added ET-1 probably reflects the very short half-life of
this peptide in vitro (19)
. It is surprising to
find that 100 nM ET-1 had a less protective effect against H/I than 10
nM ET-1. It is likely that at 100 nM ET-1, ET-1 has a toxic effect on
the cells. This is supported by the fact that addition of 10 nM ET-1 to
the wild-type astrocytes under H/I conditions actually led to more cell
death and less activation of GFAP (data not shown).
The amount of LDH released from ET-1-deficient astrocytes in response
to H/I shown in Fig. 7
was lower as compared to Fig. 5
. The reason for
this is not clear. The only difference was that the solvent for ET-1,
acetonitrile and 0.1% trifluroacetic acid, was added to the media in
these experiments. It is possible that these components may have
blunted the cells response to H/I stress.
Astrocytes are reactive to various injuries in brain as evidenced by
increased expression of GFAP. ET-1 and ET-3 are thought to be
responsible for activating the astrocytes, because injection of these
ETs into the striatum of rat brain increased the number of
GFAP-positive cells (43)
. In our in vitro H/I
model, ET-1 appeared to be essential for the induction of GFAP in the
astrocytes, but it is not clear whether ET-1 alone can induce the
expression of GFAP. ET-3 alone clearly cannot activate astrocytes since
there is lower level of GFAP in our ET-1-deficient astrocytes with ET-3
expression. Activation of astrocytes by the ETs is thought to be
mediated via the ETB receptor because BQ-788, a
selective ETB antagonist, can block this
activation (43)
. It will be interesting to see whether
this receptor antagonist has similar action in vitro because
the cell culture system is more amenable to experimental manipulations.
Our results showed that induction of GFAP in the reactive astrocytes
corresponded to resistance to H/I stress. Conversely, failure to induce
GFAP expression in ET-1-deficient astrocytes is associated with
susceptibility to H/I stress. Thus, the increase in GFAP content in
astrocytes in response to H/I injuries in the brain indicates the
brains attempt to repair the damage. It appeared that ET-1 has an
important function of protecting the astrocytes against H/I stress so
that these cells can either repair their neighboring damaged neurons or
participate in forming a protective boundary of the injured cells of
the brain.
 |
ACKNOWLEDGMENTS
|
|---|
We thank Dr. S. K. Chan (Institute of Molecular Biology, The
University of Hong Kong) and Mr. Ng Kung (Department of Biology, The
Hong Kong University of Science and Technology, Clear Water Bay) for
their technical advises for this study. This work is supported by
grants from the Hong Kong Research Grant Council to S.K.Chung.
 |
FOOTNOTES
|
|---|
1 Present address: Division of Integrative Cell
Biology, Department of Embryogenesis, Institute of Molecular Embryology
and Genetics, Kumamoto University, Kumamoto, Japan. 
Received for publication December 7, 1999.
Revision received August 15, 2000.
 |
REFERENCES
|
|---|
-
Yanagisawa, M., Kurihara, H., Kimura, S., Tomobe, Y., Kobayashi, M., Mitsui, Y., Yazaki, Y., Goto, K., Masaki, T. (1988) A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature (London) 332,411-415[Medline]
-
Inoue, A., Yanagisawa, M., Kimura, S., Kasuya, Y., Miyauchi, T., Goto, K., Masaki, T. (1989) The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc. Natl. Acad. Sci. USA 86,2863-2867[Abstract/Free Full Text]
-
Arai, H., Hori, S., Aramori, I., Ohkubo, H., Nakanishi, S. (1990) Cloning and expression of a cDNA encoding an endothelin receptor. Nature (London) 348,730-732[Medline]
-
Sakurai, T., Yanagisawa, M., Takuwa, Y., Miyazaki, H., Kimura, S., Goto, K., Masaki, T. (1990) Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature (London) 348,732-735[Medline]
-
Ruffolo, R. R., Jr (1995) Endothelin Receptors. From the Gene to the Human CRC Press, Inc Boca Raton, Fla..
-
Clarke, J. G., Benjamin, N., Larkin, S. W., Webb, D. J., Davies, G. J., Maseri, A. (1989) Endothelin is a potent long-lasting vasoconstrictor in men. Am. J. Physiol. 257,H2033-H2035[Abstract/Free Full Text]
-
de Nucci, G., Thomas, R., DOrleans-Juste, P., Antunes, E., Walder, C., Warner, T. D., Vane, J. R. (1988) Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc. Natl. Acad. Sci. USA 85,9797-9800[Abstract/Free Full Text]
-
Yamashita, K., Kataoka, Y., Niwa, M., Shigematsu, K., Himeno, A., Koizumi, S., Taniyama, K. (1993) Increased production of endothelins in the hippocampus of stroke-prone spontaneously hypertensive rats following transient forebrain ischemia: histochemical evidence. Cell. Mol. Neurobiol. 13,15-23[Medline]
-
Hirata, Y., Takagi, Y., Fukuda, Y., Marumo, F. (1989) Endothelin is a potent mitogen for rat vascular smooth muscle cells. Atherosclerosis 78,225-228[Medline]
-
MacCumber, M. W., Ross, C. A., Snyder, S. H. (1990) Endothelin in brain: receptors, mitogenesis, and biosynthesis in glial cells. Proc. Natl. Acad. Sci. USA 87,2359-2363[Abstract/Free Full Text]
-
MacNulty, E. E., Plevin, R., Wakelam, M. J. (1990) Stimulation of the hydrolysis of phosphatidylinositol 4,5-bisphosphate and phosphatidylcholine by endothelin, a complete mitogen for Rat-1 fibroblasts. Biochem. J. 272,761-766[Medline]
-
Simonson, M. S., Wann, S., Mene, P., Dubyak, G. R., Kester, M., Nakazato, Y., Sedor, J. R., Dunn, M. J. (1989) Endothelin stimulates phospholipase C. Na+/H+ exchange, c-fos expression, and mitogenesis in rat mesangial cells. J. Clin. Invest. 83,708-712
-
Vigne, P., Marsault, R., Breittmayer, J. P., Frelin, C. (1990) Endothelin stimulates phosphatidylinositol hydrolysis and DNA synthesis in brain capillary endothelial cells. Biochem. J. 266,415-420[Medline]
-
Shichiri, M., Marumo, F., and Hirata, Y. (1998) Endothelin-B receptor-mediated suppression of endothelial apoptosis. J. Cardiovasc. Pharmacol. 31 (Suppl. 1), S138S141
-
Wu-Wong, J. R., Chiou, W. J., Dickinson, R., Opgenorth, T. J. (1997) Endothelin attenuates apoptosis in human smooth muscle cells. Biochem. J. 328,733-737
-
Fuxe, K., Tinner, B., Staines, W., Hemsen, A., Hersh, L., Lundberg, J. M. (1991) Demonstration and nature of endothelin-3-like immunoreactivity in somatostatin and choline acetyltransferase-immunoreactive nerve cells of the neostriatum of the rat. Neurosci. Lett. 123,107-111[Medline]
-
Lee, M. E., de la Monte, S. M., Ng, S. C., Bloch, K. D., Quertermous, T. (1990) Expression of the potent vasoconstrictor endothelin in the human central nervous system. J. Clin. Invest. 86,141-147
-
Nakamura, S., Naruse, M., Naruse, K., Shioda, S., Nakai, Y., Uemura, H. (1993) Colocalization of immunoreactive endothelin-1 and neurohypophysial hormones in the axons of the neural lobe of the rat pituitary. Endocrinology 132,530-533[Abstract]
-
Kuwaki, T., Kurihara, H., Cao, W. H., Kurihara, Y., Unekawa, M., Yazaki, Y., Kumada, M. (1997) Physiological role of brain endothelin in the central autonomic control: from neuron to knockout mouse. Prog. Neurobiol. 51,545-579[Medline]
-
Jiang, M. H., Hoog, A., Ma, K. C., Nie, X. J., Olsson, Y., Zhang, W. W. (1993) Endothelin-1-like immunoreactivity is expressed in human reactive astrocytes. NeuroReport 4,935-937[Medline]
-
Pluta, R. M., Boock, R. J., Afshar, J. K., Clouse, K., Bacic, M., Ehrenreich, H., Oldfield, E. H. (1997) Source and cause of endothelin-1 release into cerebrospinal fluid after subarachnoid hemorrhage. J. Neurosurg. 87,287-293[Medline]
-
Yamashita, K., Niwa, M., Kataoka, Y., Shigematsu, K., Himeno, A., Tsutsumi, K., Nakano-Nakashima, M., Sakurai-Yamashita, Y., Shibata, S., Taniyama, K. (1994) Microglia with an endothelin ETB receptor aggregate in rat hippocampus CA1 subfields following transient forebrain ischemia. J. Neurochem. 63,1042-1051[Medline]
-
Yamashita, K., Kataoka, Y., Yamashita, Y. S., Himeno, A., Tsutsumi, K., Niwa, M., and Taniyama, K. (1995) Glial endothelin/nitric oxide system participates in hippocampus CA1 neuronal death of SHRSP following transient forebrain ischaemia. Clin. Exp. Pharmacol. Physiol. 22 (Suppl. 1), S277S278
-
Zhang, W. W., Badonic, T., Hoog, A., Jiang, M. H., Ma, K. C., Nie, X. J., Olsson, Y. (1994) Astrocytes in Alzheimers disease express immunoreactivity to the vasoconstrictor endothelin-1. J. Neurol. Sci. 122,90-96[Medline]
-
Tsang, M., Lam, K. T., Cheung, P. T., and Chung, S. K. (1995) Rapid induction of preproendothelin-1 mRNA in both astrocytes and cerebral endothelial cells of hypoxic/ischemic mouse brain. Neurosci. Abstr. 22, 560.7 (abstr.)
-
Kurihara, Y., Kurihara, H., Suzuki, H., Kodama, T., Maemura, K., Nagai, R., Oda, H., Kuwaki, T., Cao, W. H., Kamada, N. (1994) Elevated blood pressure and craniofacial abnormalities in mice deficient in endothelin-1. Nature (London) 368,703-710[Medline]
-
Clouthier, D. E., Hosoda, K., Richardson, J. A., Williams, S. C., Yanagisawa, H., Kuwaki, T., Kumada, M., Hammer, R. E., Yanagisawa, M. (1998) Cranial and cardiac neural crest defects in endothelin-A receptor-deficient mice. Development 125,813-824[Abstract]
-
Chan, T. S., Lin, C. X., Chan, W. Y., Chung, S. S., Chung, S. K. (1995) Mouse preproendothelin-1 gene. cDNA cloning, sequence analysis and determination of sites of expression during embryonic development. Eur. J. Biochem. 234,819-826[Medline]
-
Yu, A. C., Lee, Y. L., Eng, L. F. (1993) Astrogliosis in culture: I. The model and the effect of antisense oligonucleotides on glial fibrillary acidic protein synthesis. J. Neurosci. Res. 34,295-303[Medline]
-
Kaku, D. A., Goldberg, M. P., Choi, D. W. (1991) Antagonism of non-NMDA receptors augments the neuroprotective effect of NMDA receptor blockade in cortical cultures subjected to prolonged deprivation of oxygen and glucose. Brain Res 554,344-347[Medline]
-
Yu, A. C., Lau, L. T. (2000) Expression of interleukin-1 alpha, tumor necrosis factor alpha and interleukin-6 genes in astrocytes under ischemic injury. Neurochem. Int. 36,369-377[Medline]
-
Supattapone, S., Simpson, A. W., Ashley, C. C. (1989) Free calcium rise and mitogenesis in glial cells caused by endothelin. Biochem. Biophys. Res. Commun. 165,1115-1122[Medline]
-
Dugan, L. L., Bruno, V. M., Amagasu, S. M., Giffard, R. G. (1995) Glia modulate the response of murine cortical neurons to excitotoxicity: glia exacerbate AMPA neurotoxicity. J. Neurosci. 15,4545-4555[Abstract]
-
Rosenberg, P. A., Aizenman, E. (1989) Hundred-fold increase in neuronal vulnerability to glutamate toxicity in astrocyte-poor cultures of rat cerebral cortex [published erratum appears in Neurosci. Lett. 1990vol. 116, p. 399]. Neurosci. Lett. 103,162-168[Medline]
-
Ransom, B. R. (1992) Glial modulation of neural excitability mediated by extracellular pH: a hypothesis. Prog. Brain Res. 94,37-46[Medline]
-
Makar, T. K., Nedergaard, M., Preuss, A., Gelbard, A. S., Perumal, A. S., Cooper, A. J. (1994) Vitamin E, ascorbate, glutathione, glutathione disulfide, and enzymes of glutathione metabolism in cultures of chick astrocytes and neurons: evidence that astrocytes play an important role in antioxidative processes in the brain. J. Neurochem. 62,45-53[Medline]
-
Raps, S. P., Lai, J. C., Hertz, L., Cooper, A. J. (1989) Glutathione is present in high concentrations in cultured astrocytes but not in cultured neurons. Brain Res 493,398-401[Medline]
-
Sagara, J. I., Miura, K., Bannai, S. (1993) Maintenance of neuronal glutathione by glial cells. J. Neurochem. 61,1672-1676[Medline]
-
Hu, J., Discher, D. J., Bishopric, N. H., Webster, K. A. (1998) Hypoxia regulates expression of the endothelin-1 gene through a proximal hypoxia-inducible factor-1 binding site on the antisense strand. Biochem. Biophys. Res. Commun. 245,894-899[Medline]
-
Sasaki, Y., Hori, S., Oda, K., Okada, T., Takimoto, M. (1998) Both ET(A) and ET(B) receptors are involved in mitogen-activated protein kinase activation and DNA synthesis of astrocytes: study using ET(B) receptor-deficient rats (aganglionosis rats). Eur. J. Neurosci. 10,2984-2993[Medline]
-
Shichiri, M., Kato, H., Marumo, F., Hirata, Y. (1997) Endothelin-1 as an autocrine/paracrine apoptosis survival factor for endothelial cells [published erratum appears in Hypertension 1998, vol. 31, p. 723]. Hypertension 30,1198-1203[Abstract/Free Full Text]
-
Clouthier, D. E., Williams, S. C., Yanagisawa, H., Wieduwilt, M., Richardson, J. A., Yanagisawa, M. (2000) Signaling pathways crucial for craniofacial development revealed by endothelin-A receptor-deficient mice. Dev. Biol. 217,10-24[Medline]
-
Ishikawa, N., Takemura, M., Koyama, Y., Shigenaga, Y., Okada, T., Baba, A. (1997) Endothelins promote the activation of astrocytes in rat neostriatum through ET(B) receptors. Eur. J. Neurosci. 9,895-901[Medline]